{"id":"ticagrelor-asa-bivalirudin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a P2Y12 receptor antagonist that blocks ADP-mediated platelet activation, while aspirin irreversibly inhibits cyclooxygenase-1 to reduce thromboxane A2 production. Bivalirudin is a direct thrombin inhibitor that prevents fibrin formation and thrombus propagation. Together, this triple antithrombotic regimen targets multiple pathways of coagulation and platelet function to reduce ischemic cardiovascular events.","oneSentence":"This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:46.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with percutaneous coronary intervention"},{"name":"Prevention of stent thrombosis and recurrent ischemic events"}]},"trialDetails":[{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT01642238","phase":"PHASE4","title":"Antithrombotic Effects of Ticagrelor Versus Clopidogrel","status":"COMPLETED","sponsor":"Juan J Badimon","startDate":"2012-07","conditions":"Acute Coronary Syndrome","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilinta (ticagrelor","Aspirin (ASA)","Angiomax (bivalirudin)"],"phase":"marketed","status":"active","brandName":"Ticagrelor + ASA + Bivalirudin","genericName":"Ticagrelor + ASA + Bivalirudin","companyName":"Juan J Badimon","companyId":"juan-j-badimon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Prevention of stent thrombosis and recurrent ischemic events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}